← Back to all substances
N

escitalopram

231ms
Level 1

✓ What this shows

  • • Reported adverse events from FDA FAERS
  • • Descriptive statistics from a locked corpus
  • • Data verified with cryptographic hashes

✗ What this is NOT

  • • Not medical advice or recommendations
  • • Not proof of causality
  • • Not a complete safety profile

About this substance

1 INDICATIONS AND USAGE Escitalopram is indicated for the treatment of: major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older. generalized anxiety disorder (GAD) in adults. Additional pediatric use information is approved for AbbVie Inc.’s Lexapro (escitalopram) ...

Known as: Escitalopram Oral Solution
Route: ORAL
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
72,661
Total in FDA
87%
Serious Reports
67
Fatal Outcomes

Seriousness

Serious
433
Non-Serious
67

Sex Distribution

Male
157
Female
326
Unknown
17

Age Distribution

0-17
25
18-40
76
41-64
180
65-84
104
85+
38
Unknown
77

Outcomes

Recovered/Resolved
520
Recovering/Resolving
110
Not Recovered/Not Resolved
248
Recovered with Sequelae
18
Fatal
67
Unknown
850

Top Reported Reactions (click to view reports)

Verification Data

Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-51f852
ℹThis output reports adverse events from FDA FAERS. It does not constitute medical advice.

Molecular Structure (reference)

Structural visualization for identification only.

This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.

Loading structure...